- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04038112
Method of Level (MOL) Therapy for Psychosis
July 26, 2019 updated by: Jadwiga Nazimek, University of Manchester
A Case Series of Method of Levels (MOL) Therapy for People Experiencing Psychosis
The study is a systematic case replication series of a new psychological therapy Method of Levels (MOL) for people who experience psychosis.
Between 6 and 8 people with psychosis who receive services from CMHT will be recruited.
Participants will complete baseline questionnaires measuring their symptoms and distress and will be offered up to 12 sessions of MOL.
Following the completion of therapy they will complete the questionnaires measuring symptoms and distress again.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Psychosis is an enduring and distressing mental illness which can cause high levels of disability.
Recommended treatments include antipsychotic medication and Cognitive Behaviour Therapy (CBT).
Antipsychotic drugs cause serious negative side effects which are intolerable for some patients.
CBT can be difficult to conduct in the presence of comorbid problems and can be too demanding for some patients.
Both medication and CBT sometimes fail to sufficiently reduce the symptoms.
Method of Levels (MOL) is a flexible, short-term, cognitive therapy informed by a theory that explains the underpinnings of psychological distress and the mechanisms of action in effective therapy.
The purpose of the current study is to evaluate the utility of MOL for individuals with non-affective psychosis who are under the care of secondary mental health services.
A case series will explore the efficacy of MOL for the levels of symptoms, distress and general functioning.
MOL will be offered to 6-8 individuals with psychosis within a flexible appointment scheduling system.
Levels of symptoms, distress and general functioning will be measured before and after treatment.
Open feedback interviews following the completion of treatment will allow us to evaluate the patients' experience of MOL.
The project will provide preliminary data which will inform clinical practice and contribute to large scale research of MOL.
Study Type
Interventional
Enrollment (Anticipated)
6
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants have to be registered with a Community Mental Health Services
- Participants need to either meet ICD-10 criteria for schizophrenia, schizoaffective disorder and delusional disorder or meet entry criteria for an Early Intervention for Psychosis service.
Exclusion Criteria:
- Known moderate to severe learning disability
- Known organic basis of symptoms
- Known lack of capacity to consent to participating in research
- Lack of fluency in English (since MOL therapy will be conducted in English and due to use of standardised assessment tools). This will be determined by the researcher.
- Acute inpatient status
- A primary diagnosis of a drug or alcohol dependency
- Concurrent psychological therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Method of Levels (MOL)
all participants will be offered intervention
|
Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Community Assessment of Psychic Experiences (CAPE)
Time Frame: 12 weeks
|
Self-administered questionnaire, measure of symptoms of psychosis and associated distress.
Total scores range from 42 to 168 on both dimensions (symptoms and distress).
Higher scores indicate higher frequency of symptoms and higher distress.
|
12 weeks
|
|
Reorganization of Conflict Scale (ROC)
Time Frame: 12 weeks
|
Self-administered questionnaire measures the degree of reorganization (resolution) of internal conflict.
Scores range from 0 to 110, with higher scores indicating higher level of internal conflict resolution.
|
12 weeks
|
|
Outcome Rating Scale
Time Frame: 12 weeks
|
Self-administered visual analogue scale, measure of wellbeing.
Scores range from 0 to 40, with higher scores indicating higher level of wellbeing.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2019
Primary Completion (Anticipated)
January 31, 2020
Study Completion (Anticipated)
March 31, 2020
Study Registration Dates
First Submitted
July 24, 2019
First Submitted That Met QC Criteria
July 26, 2019
First Posted (Actual)
July 30, 2019
Study Record Updates
Last Update Posted (Actual)
July 30, 2019
Last Update Submitted That Met QC Criteria
July 26, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 257300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Columbia UniversityNational Institute of Mental Health (NIMH); University of California, Davis; University... and other collaboratorsRecruitingClinical High Risk | First Episode Psychosis | Early PsychosisUnited States
-
University of OxfordWellcome Trust; Jazz PharmaceuticalsNot yet recruitingClinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Clinical High Risk for Developing PsychosisUnited Kingdom, Italy, Greece, Finland, Germany, Netherlands, Austria, Canada, Spain, Switzerland
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Enrolling by invitationFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Elazığ Mental Health and Diseases HospitalRecruitingMethamphetamine Induced PsychosisTurkey (Türkiye)
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingClinical High Risk | First Episode Psychosis | Early PsychosisUnited States
-
Université de SherbrookeBaszucki Brain Research FundNot yet recruitingMetabolic Disease | Psychosis; Episode | First Episose PsychosisCanada
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
University of OxfordHospital General Universitario Gregorio Marañon; Charite University, Berlin... and other collaboratorsNot yet recruitingPsychosis | Treatment Resistant PsychosisSpain, United Kingdom, Germany, Israel, Greece, Italy, Netherlands, Switzerland
Clinical Trials on psychological therapy Method of Levels (MOL)
-
University of ManchesterCompletedDepression | Anxiety | Mental Health Wellness 1United Kingdom
-
University of ManchesterCompletedBipolar Spectrum DisorderUnited Kingdom
-
University of ManchesterCompletedIndividuals Presenting to Crisis ServicesUnited Kingdom
-
University of ManchesterCompleted
-
University of ManchesterNot yet recruitingMental HealthUnited Kingdom
-
University of ManchesterCompletedMedication Adherence | PsychosisUnited Kingdom
-
Policlinico Universitario, CataniaRecruitingNewborn Morbidity | Premature Infant DiseaseItaly
-
Wenzhou Medical UniversityWuhan University; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaboratorsCompletedDepression | Breast Cancer | AnxietyChina
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Thomas Jefferson UniversityCompleted